Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial

Kimball AB, Bechara FG, Badat A, et al. Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial. Br J Dermatol. 2025;192(4):629-640. doi:10.1093/bjd/ljae469. | PMID: N/A

This extension trial reports 104-week results evaluating the long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa, building on data from the SUNSHINE and SUNRISE studies.

Key Learning Points

• •
  Secukinumab maintains significant efficacy with an acceptable safety profile through 104 weeks in moderate-to-severe hidradenitis suppurativa patients.
• •
  Long-term treatment supports sustained clinical benefits and manageable adverse events.